Geron (GERN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Geron (GERN)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: BulbaMan who wrote (26)	2/26/1997 11:21:00 AM
From: louis mason	of 50

Dear Marty, How broadly do you think that Geron's patent will be enforced with respect to the specifics of the telomerase inhibition issue. For example, I guess that Geron was counting on targeting the RNA componant of the holoenzyme- but I recently talked with a scientist on the East Coast who said that a mouse line was produced to address this issue, and they are now in their third generation (RNA knock-outs) without obvious telomere shortening. So, can Amgen now target the specific telomerase homolog protein that they have cloned (RNA binding componant) - since they were the first ones to clone it? Or, do you think that Geron would insist that they are the only ones who can look for agents targeting this component? I'm also wondering if Geron could ever be a take over target for Amgen? I wonder if a direct collaboration might be out of the question because I talked to someone who said that potential Amgen projects with Geron were pretty much side-lined due to the Upjohn contract! I'm just wondering if the competition is starting to heat up in this previously Geron dominated field. sincerely .. louis mason

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next